Navigation Links
Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses

ARLINGTON, Va., Jan. 25 /PRNewswire-USNewswire/ -- A report released today by The Cornucopia Institute presents research indicating that new additives placed in infant formula are seriously endangering the health of some formula-fed newborns and toddlers.

The report, 'Replacing Mother--Imitating Human Breast Milk in the Laboratory,' details research questioning the alleged benefits of adding "novel" omega-3 fatty acids, produced in laboratories and extracted from algae and fungus, into infant formulas. The additives raised health and safety red flags during preapproval testing while aggressive marketing campaigns by some infant formula manufacturers appear to have encouraged new mothers to give up nursing for the questionable products.

"When I worked in the hospital's neonatal ward, the nurses all called it 'the diarrhea formula'," says Sam Heather Doak, LPN, IBCLC, from Marietta, Ohio. "We've seen infants, tiny little humans, with diarrhea that just wouldn't stop after being given this formula." For infants, virulent and long-term diarrhea is considered a serious and life-threatening event.

The infant formula referenced by Doak was supplemented with Martek Biosciences Corporation's laboratory-produced oils containing DHA and ARA. DHA, an omega-3 fatty acid, and ARA, an omega-6 fatty acid, are naturally found in human breast milk and are considered important nutrients for infants.

But laboratory-produced DHASCO and ARASCO (Martek's names for their proprietary oils) are materially different from the fats found in a mother's breast milk. Martek's products are extracted from fermented algae and fungus, with the use of the neurotoxic solvent hexane. They contain only 40 to 50% DHA and ARA, with the balance from sunflower oil and other components, including some not found in human breast milk and never before a part of the human infant diet.

"It's true that DHA and ARA are important nutrients for developing infants--that's why they're found in human breast milk. But we have also seen that some infants are experiencing side effects like diarrhea from consuming the manufactured DHA and ARA oils in formula," says Jimi Francis, Ph.D., a biochemist specializing in DHA in infant nutrition at the Allie M. Lee Laboratory for Omega-3 Research at the University of Nevada at Reno. Also, humans produce DHA and ARA on their own from other fats.

The Cornucopia Institute, a Wisconsin-based farm and food policy research group and corporate watchdog, presented its report, in partnership with the National Alliance for Breastfeeding Advocacy, to government officials and medical professionals at today's meeting of the U.S. Breastfeeding Committee.

"While infant formula manufacturers claim that these oils are perfectly safe and necessary for proper development, our report provides a more detailed picture," said Charlotte Vallaeys, Farm and Food Policy Analyst with the Cornucopia Institute and lead author of the report. "We investigated how a toxic chemical is used as processing agents in the manufacturing process, the inadequate testing for safety, and most importantly, how some infants are experiencing serious adverse reactions from formula supplemented with these oils," Vallaeys added.

"This report presents a disturbing look at the novel ingredients in infant formula," says Marsha Walker, Executive Director of the National Alliance for Breastfeeding Advocacy. "The FDA has received scores of adverse reports on effects of these ingredients, but, to date, the public's only access to these is through Cornucopia's Freedom of Information Act request. This report will help alert the health care community and federal agencies."

Cornucopia and the National Alliance for Breastfeeding Advocacy are now petitioning the FDA for a warning label alerting parents of the range of possible complications from DHA/ARA-supplemented formula.

For more, visit Cornucopia's website at

SOURCE The Cornucopia Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
2. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
5. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
6. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
7. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
8. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
9. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
10. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
11. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
Post Your Comments:
(Date:11/27/2015)... NEW YORK , November 27, 2015 ... health system is set to go online. The potential ... and processes is vast and far from fully exploited ... access to patient health records, either via mobile tablet ... ) --> ) ...
(Date:11/27/2015)... , Nov. 27, 2015 Research and ... the "Global Intrauterine Devices Market 2015-2019" report ... --> In this report, the author the ... devices market for 2015-2019. To calculate the market size, ... following type of products: Hormonal IUDs and copper IUDs. ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
Breaking Medicine Technology:
(Date:11/30/2015)... Maryland (PRWEB) , ... November 30, 2015 , ... ... interactions could be of critical importance to the medical schools of the future. ... exhibited its healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized by ...
(Date:11/30/2015)... ... 30, 2015 , ... TransPack Volume 6 features 30 customizable transitions created exclusively ... transitions to wipes with blur & drop shadow options. Utilize the controls in ... one clip to the next with TransPack's easily customizable styles. , TransPack ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... healthcare professionals worldwide today released the results of a survey of educational needs ... and Africa found a growing global demand for high quality online and face-to-face ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... to announce their strategic partnership at the Radiological Society of North America ... Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, announced their ...
(Date:11/30/2015)... ... November 30, 2015 , ... Several significant coding-related changes are ... likely to include new codes for spine and hip X-rays, paravertebral facet blocks ... of code changes in musculoskeletal, radiology and nervous system sections on an Orthopedic ...
Breaking Medicine News(10 mins):